Advertisement
Advertisement
U.S. markets open in 6 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.36-0.01 (-0.06%)
At close: 4:00PM EDT
Advertisement

Cyteir Therapeutics, Inc.

128 Spring Street
Building A Suite 510
Lexington, MA 02421
United States
857 285 4140
http://cyteir.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph S. ZakrzewskiIndependent Investor & Chairman60.05kN/A1962
Dr. Markus F. Renschler M.D.Pres, CEO & Director630kN/A1961
Mr. Timothy RombergerIndependent DirectorN/AN/A1972
Dr. Paul Secrist Ph.D.Chief Scientific Officer265.23kN/A1966
Mr. Andrew W. GengosChief Bus. Officer436.51kN/A1964
Dr. Kevin MillsCo-FounderN/AN/AN/A
Mr. David G. GaieroVP of Fin.N/AN/A1979
Ms. Lisa A. HayesVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Gale CohenVP of HRN/AN/AN/A
Dr. Tom O'Shea Ph.D.Sr. VP of Clinical Pharmacology & Preclinical Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyteir Therapeutics, Inc. operates as a clinical-stage oncology company that develops novel therapeutics based on the biology of DNA repair for the treatment of cancer and synthetic lethality therapeutics for autoimmune diseases. The company engages in manufacturing therapeutics that provide precision targeting of key DNA repair factors to induce diseased cells to self-destruct by DNA damage overload and uses an integrated drug development platform that modulates the imbalance between DNA damage and repair for the therapeutic effect to deliver a pipeline of small molecule therapeutics with a range of potential disease state applications. It provides CYT-0851, an oral small-molecule inhibitor of RAD51-mediated DNA repair. It focuses on providing treatments for a range of hematological malignancies, solid tumors, and chronic autoimmune disorders. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Corporate Governance

Cyteir Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement